Chip Petricoin on the Discovery of New Biomarkers

Emanuel F. Petricoin, III, PhD
Published: Monday, May 20, 2013

Emanuel F. “Chip” Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

There have been many large, publicly-funded biomarker discovery efforts, Petricoin says. The National Cancer Institute (NCI) has increase its effort to more methodically develop, discover, evaluate, and validate biomarkers. The process has been supported by the fact that many of these biomarkers have been approved by the FDA.

The NCI has also developed biomarkers that have translated well from the clinical to commercial setting in imaging, high-risk population screening, and recurrence monitoring.
 
Emanuel F. “Chip” Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

There have been many large, publicly-funded biomarker discovery efforts, Petricoin says. The National Cancer Institute (NCI) has increase its effort to more methodically develop, discover, evaluate, and validate biomarkers. The process has been supported by the fact that many of these biomarkers have been approved by the FDA.

The NCI has also developed biomarkers that have translated well from the clinical to commercial setting in imaging, high-risk population screening, and recurrence monitoring.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x